度戈妥珠單抗

度戈妥珠單抗（INN：Duligotuzumab）是一種雙特異性人源化IgG₁單株抗體，設計用於治療癌症。它充當免疫調節劑並與EGFR和HER3（英語：ERBB3）結合。^[1]^[2]它由羅氏公司開發。針對頭頸癌和結直腸癌的臨床開發已停止，但與考比替尼聯合使用的I期試驗正在評估實體瘤治療的安全性。^[3]

參考資料

^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107 (PDF). WHO Drug Information. 2012, 26 (2) [2024-01-22]. （原始內容存檔 (PDF)於2016-03-04）.
^ Hill, Andrew G.; Findlay, Michael P.; Burge, Matthew E.; Jackson, Christopher; Alfonso, Pilar Garcia; Samuel, Leslie; Ganju, Vinod; Karthaus, Meinolf; Amatu, Alessio; Jeffery, Mark; Bartolomeo, Maria Di. Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2018-05-15, 24 (10) [2024-01-22]. ISSN 1557-3265. PMID 29506988. doi:10.1158/1078-0432.CCR-17-0646. （原始內容存檔於2024-03-14）.
^ Duligotuzumab. AdisInsight. [2024-01-22]. （原始內容存檔於2021-11-19）.